That is pretty odd that the media are picking it up now. I still don't see much reason to be very concerned about BA.2 beyond the typical level of concern about Omicron overall--and I think you're on the same page.
The UK data are pretty interesting! Thanks for sharing.
May I humbly suggest that you simply use the SHOW ME THE DATA image on every one of your posts? Everyone will love it - and that way it becomes an image that immediately gets identified with your posts on Social Media.
Vivek Murthy's comments at the last White House COVID-19 Response Team briefing, as well as chatter on social media, suggest that Pfizer will have some new real-world effectiveness data to present for the 2-4 cohort. I hope they'll also be able to provide some interim data on the third dose in this age group.
Speaking of Spikevax and pediatric vaccines: what on Earth is going on with the Moderna EUA request for adolescents? They submitted data in May 2021, after which the FDA said they wanted more time to evaluate myocarditis risk, and wouldn't able to complete their review until January 2022. In the meantime, Moderna reported positive safety and immunogenicity data its trial in ages 6-11, and is expecting data for the 2-5 cohort next month. But the FDA has given no indication of when they'll make a determination for ages 12-17.
There's not exactly an urgent need for Spikevax in the 12-17 or 6-11 cohorts, given that they already have access to the Pfizer-BioNTech vaccine. But it will be rather awkward if Moderna produces positive data for a 2-5 vaccine, only for its submission to be stalled due to the holdup with older age groups -- especially if the FDA and CDC don't sign off of Pfizer's submission for young children later this month.
Who knows. Regulatory submissions are fantastically complicated and it's easy to get caught up in a back-and-forth with regulators. Moderna is a young company, also, and this was their first marketed product. The may be a bit of an experience gap, too. I don't know.
I'm starting to see BA.2 hysteria in the popular media. It's odd, since the first wave of publicity was over a week ago.
A report from the UK says that BA.2, interestingly, is less able to avoid existing vaccine-induced immunity than Omicron BA.1: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1050721/Vaccine-surveillance-report-week-4.pdf
That is pretty odd that the media are picking it up now. I still don't see much reason to be very concerned about BA.2 beyond the typical level of concern about Omicron overall--and I think you're on the same page.
The UK data are pretty interesting! Thanks for sharing.
Today's footnote applies to so much.
May I humbly suggest that you simply use the SHOW ME THE DATA image on every one of your posts? Everyone will love it - and that way it becomes an image that immediately gets identified with your posts on Social Media.
Vivek Murthy's comments at the last White House COVID-19 Response Team briefing, as well as chatter on social media, suggest that Pfizer will have some new real-world effectiveness data to present for the 2-4 cohort. I hope they'll also be able to provide some interim data on the third dose in this age group.
Speaking of Spikevax and pediatric vaccines: what on Earth is going on with the Moderna EUA request for adolescents? They submitted data in May 2021, after which the FDA said they wanted more time to evaluate myocarditis risk, and wouldn't able to complete their review until January 2022. In the meantime, Moderna reported positive safety and immunogenicity data its trial in ages 6-11, and is expecting data for the 2-5 cohort next month. But the FDA has given no indication of when they'll make a determination for ages 12-17.
There's not exactly an urgent need for Spikevax in the 12-17 or 6-11 cohorts, given that they already have access to the Pfizer-BioNTech vaccine. But it will be rather awkward if Moderna produces positive data for a 2-5 vaccine, only for its submission to be stalled due to the holdup with older age groups -- especially if the FDA and CDC don't sign off of Pfizer's submission for young children later this month.
Who knows. Regulatory submissions are fantastically complicated and it's easy to get caught up in a back-and-forth with regulators. Moderna is a young company, also, and this was their first marketed product. The may be a bit of an experience gap, too. I don't know.